Erasca (ERAS) Cash from Investing Activities (2020 - 2026)
Erasca posted quarterly Cash from Investing Activities of -$243.8 million for Q1 2026, down 811.6% year-on-year from $34.3 million in Q1 2025, and down 1086.73% on a QoQ basis from $24.7 million in Q4 2025.
Erasca (ERAS) has 7 years of Cash from Investing Activities data on file, last reported at -$243.8 million in Q1 2026.
- For the quarter ending Q1 2026, Cash from Investing Activities fell 811.6% year-over-year to -$243.8 million; the trailing twelve-month figure through Mar 2026 stood at -$177.7 million (down 34.27% YoY), and the FY2025 full-year result was $100.4 million, up 164.12% from the prior year.
- Cash from Investing Activities for Q1 2026 stood at -$243.8 million, down from $24.7 million in the prior quarter.
- Across five years, Cash from Investing Activities topped out at $34.3 million in Q1 2025 and bottomed at -$243.8 million in Q1 2026.
- The 5-year median for Cash from Investing Activities is -$1.8 million (2022), against an average of -$27.2 million.
- The widest annual swing landed in 2023, when Cash from Investing Activities soared 920.18%; it then slumped 5561.98% in 2024.
- A 5-year view of Cash from Investing Activities shows it stood at -$4.9 million in 2022, then soared by 193.38% to $4.5 million in 2023, then jumped by 397.62% to $22.6 million in 2024, then advanced by 9.26% to $24.7 million in 2025, then sank by 1086.73% to -$243.8 million in 2026.
- The last three Cash from Investing Activities figures came in at -$243.8 million (Q1 2026), $24.7 million (Q4 2025), and $25.7 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -2.89 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 638.50 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | -431.90 Mn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | -428.90 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | -25.54 Mn |
| 10 | Erasca | 4.21 Bn | 3.97 Bn | - | -243.83 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -243.83 Mn |
| Mar 31, 2026 | -243.83 Mn |
| Dec 31, 2025 | 24.71 Mn |
| Dec 31, 2025 | 24.71 Mn |
| Sep 30, 2025 | 25.70 Mn |
| Sep 30, 2025 | 25.70 Mn |
| Jun 30, 2025 | 15.75 Mn |
| Jun 30, 2025 | 15.75 Mn |
| Mar 31, 2025 | 34.27 Mn |
| Mar 31, 2025 | 34.27 Mn |
| Dec 31, 2024 | 22.62 Mn |
| Dec 31, 2024 | 22.62 Mn |
| Sep 30, 2024 | -102.60 Mn |
| Sep 30, 2024 | -102.60 Mn |
| Jun 30, 2024 | -86.61 Mn |
| Jun 30, 2024 | -86.61 Mn |
| Mar 31, 2024 | 9.97 Mn |
| Mar 31, 2024 | 9.97 Mn |
| Dec 31, 2023 | 4.55 Mn |
| Dec 31, 2023 | 4.55 Mn |
| Sep 30, 2023 | -1.81 Mn |
| Sep 30, 2023 | -1.81 Mn |
| Jun 30, 2023 | -108.67 Mn |
| Jun 30, 2023 | -108.67 Mn |
| Mar 31, 2023 | 14.71 Mn |
| Mar 31, 2023 | 14.71 Mn |
| Dec 31, 2022 | -4.87 Mn |
| Dec 31, 2022 | -4.87 Mn |
| Sep 30, 2022 | -55.23 Mn |
| Sep 30, 2022 | -55.23 Mn |
| Jun 30, 2022 | -9.19 Mn |
| Jun 30, 2022 | -9.19 Mn |
| Mar 31, 2022 | -1.79 Mn |
| Mar 31, 2022 | -1.79 Mn |
| Dec 31, 2021 | -63.95 Mn |
| Dec 31, 2021 | -63.95 Mn |
| Sep 30, 2021 | -4.94 Mn |
| Sep 30, 2021 | -4.94 Mn |
| Jun 30, 2021 | 4.46 Mn |
| Jun 30, 2021 | 4.46 Mn |
| Mar 31, 2021 | -162,000.00 |
| Mar 31, 2021 | -162,000.00 |
| Dec 31, 2020 | 16.57 Mn |
| Dec 31, 2020 | 16.57 Mn |
| Sep 30, 2020 | -49.15 Mn |
| Sep 30, 2020 | -49.15 Mn |